

3. Lobo RA, Kletzky OA, Campeau JD & diZerega GS, Elevated bioactive luteinizing hormone in women with the polycystic ovary syndrome. *Fertil Steril*, 1983; 39: 674-8.
4. Polson DW, Adams J, Wadsworth J & Franks S, Polycystic ovaries — a common finding in normal women. *Lancet*, 1988; 1: 870-2.
5. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. *Fertil Steril*, 2004; 81: 19-25.
6. Azziz R, Controversy in clinical endocrinology: diagnosis of polycystic ovarian syndrome: the Rotterdam criteria are premature. *J Clin Endocrinol Metab*, 2006; 91: 781-5.
7. Boomsma CM, Eijkemans MJ, Hughes EG & al, A meta-analysis of pregnancy outcomes in women with polycystic ovary syndrome. *Hum Reprod Update*, 2006; 12: 673-83.
8. Burghen GA, Givens JR & Kitabchi AE, Correlation of hyperandrogenism with hyperinsulinism in polycystic ovarian disease. *Journal of Clinical Endocrinology and Medicine* 1980; 50: 113-116.
9. Chang RJ, Nakamura RM, Judd HL & Kaplan SA, Insulin resistance in nonobese patients with polycystic ovary syndrome. *J Clin Endocrinol & Metabol*, 1983; 57: 356-359.
10. Coviello AD, Legro RS & Dunaif A, Adolescent girls with polycystic ovary syndrome have an increased risk of the metabolic syndrome associated with increasing androgen levels independent of obesity and insulin resistance. *J Clin Endocrinol Metab*, 2006; 91: 492-7.
11. Jialal I, Naiker P, Reddi K & al, Evidence for insulin resistance in nonobese patients with polycystic ovarian disease. *J Clin Endocrinol & Metabol*, 1987; 64: 1066-1069.
12. Ovesen P, Moller J, Ingerslev HJ & al, Normal basal and insulin stimulated fuel metabolism in lean women with polycystic ovary syndrome. *J Clin Endocrinol & Metabol*, 1993; 77: 1636-1640.
13. Holte J, Bergh T, Berne C & al, Enhanced early insulin response to glucose in relation to insulin resistance in women with polycystic ovary syndrome and normal glucose tolerance. *J Clin Endocrinol & Metabol*, 1994; 78: 1052-1058.
14. McCartney CR, Prendergast KA, Chhabra S & al, The association of obesity and hyperandrogenemia during the pubertal transition in girls: obesity as a potential factor in the genesis of postpubertal hyperandrogenism. *J Clin Endocrinol Metab*, 2006; 91: 1714-22.
15. Robinson S, Kiddy D, Gelding SV & al, The relation of insulin sensitivity to menstrual pattern in women with hyperandrogenism and polycystic ovaries. *Clin Endocrinol*, 1993; 39: 351-355.
16. Berneis K, Rizzo M, Lazzaroni V & al, Atherogenic lipoprotein phenotype and low-density lipoproteins size and subclasses in women with polycystic ovary syndrome. *J Clin Endocrinol Metab*, 2006; 24 [Epub ahead of print].
17. Blass KM, Newschaffer CJ, Klag MJ & Bush TL, Plasma lipoprotein levels as predictor of cardiovascular death in women. *Arch Intern Med*, 1993; 153: 2209-2216.
18. Rajkhowa M, Neary RH, Knmptala P & al, Altered composition of high density lipoproteins in women with polycystic ovary syndrome. *J Clin Endocrinol & Metabol*, 1997; 82: 3389-3394.
19. Lobo RA & Carmina E, *Mishell's Textbook of Infertility, Contraception, and Reproductive Endocrinology*. 4th ed. Boston: Blackwell; 1997: 363-83.
20. Ek I, Arner P, Bergqvist A & al, Impaired adipocyte lipolysis in nonobese women with the polycystic ovary syndrome: a possible link to insulin resistance? *J Clin Endocrinol Metab*, 1997; 82: 1147-53.
21. Glueck CJ, Papanna R, Wang P & al, Incidence and treatment of metabolic syndrome in newly referred women with confirmed polycystic ovarian syndrome. *Metabolism*, 2003; 52: 908-15.
22. Zimmermann S, Phillips RA, Dunaif A & al, Polycystic ovary syndrome: lack of hypertension despite profound insulin resistance. *J Clin Endocrinol Metab*, 1992; 75: 508-13.
23. Dahlgren E, Janson PO, Johansson S & al, Polycystic ovary syndrome and risk for myocardial infarction: evaluated from a risk factor model based on a prospective population study of women. *Acta Obstet Gynecol Scand*, 1992; 71: 599-604.
24. Dahlgren E, Johansson PO, Lindstedt G & al, Women with polycystic ovary syndrome wedge resected in 1956 to 1965: a long-term follow-up focusing on natural history and circulating hormones. *Fertil Steril*, 1992; 57: 505-13.
25. Kelly CJG, Speirs A, Gould GW & al, Altered vascular function in young women with polycystic ovary syndrome. *J Clin Endocrinol Metab*, 2002; 87: 742-6.
26. Paradisi G, Steinberg HO, Hempfling A & al, Polycystic ovary syndrome is associated with endothelial dysfunction. *Circulation*, 2001; 103: 1410-5.
27. Mather KJ, Verma S, Corenblum B & Anderson TJ, Normal endothelial function despite insulin resistance in healthy women with the polycystic ovary syndrome. *J Clin Endocrinol Metab*, 2000; 85: 1851-6.
28. Paradisi G, Steinberg HO, Shepard MK & al, Troglitazone therapy improves endothelial function to near normal levels in women with polycystic ovary syndrome. *J Clin Endocrinol Metab*, 2003; 88: 576-80.
29. Wild RA, Grubb B, Hartz A & al, Clinical signs of androgen excess as risk factors for coronary artery disease. *Fertil Steril*, 1990; 54: 255-9.
30. Birdsall MA, Farquhar CM & White HD, Association between polycystic ovaries and extent of coronary artery disease in women having cardiac catheterisation. *Annals of Intern Med*, 1997; 126: 32-35.
31. Dahlgren E, Janson PO, Johansson S & al, Polycystic ovary syndrome and risk for myocardial infarction. Evaluated from a risk factor model based on a prospective population study of women. *Acta Obstet Gynecol Scand*, 1992; 71: 559-604.
32. Handa N, Matsumoto M, Meade H & al, Ultrasonic evaluation of early carotid atherosclerosis. *Stroke*, 1990; 21: 1567-1572.
33. Guzick DS, Talbott EO, Sutton-Tyrell K & al, Carotid atherosclerosis in women with polycystic ovary syndrome: initial results from case control study. *Am J Obstetr & Gynecol*, 1996; 174: 1224-1229.